Unjha Formulations Ltd (UNJHAFOR) — shareholding pattern, promoter holding, financials and share price
About Unjha Formulations Ltd (UNJHAFOR)
Unjha Formulations Ltd operates in the Pharmaceuticals industry, within the Healthcare sector. It trades on the NSE as UNJHAFOR and on the BSE under scrip code 531762. Its ISIN is INE576D01015.
Incorporated in 1991, Unjha Formulations Ltd is a manufacturer and exporter of psyllium husk-based products. [1]
Unjha Formulations Ltd is a prominent manufacturer of pharmaceutical formulations including liquids, powders, tablets, capsules, and injectables. They are pioneers in Ayurvedic Isabgol products.
The company operates two major divisions for human and veterinary products, making it one of the largest Isabgol product manufacturers in India.
Listed peers in Pharmaceuticals: Starsource Multitrade Ltd, Ortin Global Ltd, Saroja Pharma Industries India Ltd, Beryl Drugs Ltd, Colinz Laboratories Ltd, Vivanza Biosciences Ltd.
Valuation & Returns
10 Jul 2026At ₹24.28 a share on 10 Jul 2026, Unjha Formulations Ltd (UNJHAFOR) was valued at a price-to-earnings ratio of 15.32x against an industry P/E of 36.41x and a price-to-book of 3.47x on a book value of ₹7.01 per share as of Mar 2025. Solomo computes return on equity of 22.62% and return on capital employed of 30.59% from filed results. Earnings ratios use standalone results for the twelve months Jun 2025 to Mar 2026.
- P/E
- 15.32x
- Industry P/E
- 36.41x
- P/B
- 3.47x
- EPS (TTM)
- ₹1.58
- Book value / share
- ₹7.01
- ROE
- 22.62%
- ROCE
- 30.59%
- ROA
- 15.58%
- Debt / equity
- 0x
- Dividend yield
- 0%
- EBITDA margin
- 7.06%
- 52-week range
- ₹17.52 – ₹30.4
Ratios are computed from filed results and the last recorded price. Not investment advice.
Financial Performance
Mar 2026In the year ended Mar 2026, Unjha Formulations Ltd (UNJHAFOR) reported revenue of ₹15.75 crore, net profit of ₹0.7 crore and earnings per share of ₹1.56. That compares with revenue of ₹13.86 crore and net profit of ₹0.41 crore in Mar 2025. Figures are standalone, as filed with the exchanges.
In the quarter ended Mar 2026, revenue was ₹3.33 crore and net profit ₹-0.74 crore (standalone).
| Metric | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|
| Revenue (₹ cr) | 14.16 | 13.15 | 18.5 | 13.86 | 15.75 |
| Net profit (₹ cr) | 0.25 | 0.28 | 0.28 | 0.41 | 0.7 |
| EPS (₹) | 0.56 | 0.62 | 0.62 | 0.92 | 1.56 |
| Measure | 10Y | 5Y | 3Y | 1Y |
|---|---|---|---|---|
| Sales growth | 3.28% | 5.51% | -0.72% | -25.08% |
| Profit growth | 5.24% | 5.73% | 17.30% | 46.43% |
Ownership Summary
Jun 2026As of Jun 2026, promoters hold 36.92% of Unjha Formulations Ltd (UNJHAFOR) (unchanged from the previous quarter). Market capitalisation was ₹11 crore on 10 Jul 2026. Shareholding is filed quarterly with BSE and NSE; Solomo carries every filing back to Mar 2001.
Largest disclosed public shareholders in Jun 2026: HUF 6.19%, Esha Mayank Patel 1.6%, Deep Mayankbhai Patel 1.29%, Manishkumar Joitaram Patel 1.28%, Narveer Yadav 1.17%, Jatinkumar Babulal Patel 1.06%. Only stakes above the 1% disclosure threshold are named in filings.
| Quarter | Promoter | Pledged | FII | DII | Public |
|---|---|---|---|---|---|
| Jun 2026 | 36.92% | - | - | - | 63.08% |
| Mar 2026 | 36.92% | - | - | - | 63.08% |
| Dec 2025 | 36.92% | - | - | - | 63.08% |
| Sep 2025 | 36.92% | - | - | - | 63.08% |
| Jun 2025 | 36.92% | - | - | - | 63.08% |
| Mar 2025 | 36.92% | - | - | - | 63.08% |
| Dec 2024 | 36.92% | - | - | - | 63.08% |
| Sep 2024 | 36.92% | - | - | - | 63.08% |